Immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This study is tracking how well a combination of two immunotherapy medicines (iparomlimab and tuvonralimab) works in people with advanced cancers. It's a real-world study, meaning you get the treatment as part of your regular care, and the researchers observe the results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has grown or spread after trying at least one standard treatment, and you can't have or don't want more standard therapy.
- Certain cancer types are included: colorectal, liver, esophagus, bile duct, pancreas, stomach, breast, non-small cell lung, small cell lung, or soft tissue sarcoma.
- You are able to care for yourself (ECOG score 0-2) and are expected to live at least 12 weeks.
- You have at least one tumor that can be measured on scans.
- Your organs (blood, liver, kidneys, etc.) are working well enough, as shown by blood and urine tests.
- You have not had a previous immune checkpoint inhibitor (like ipilimumab, nivolumab, or pembrolizumab).
- If you could become pregnant (or have a partner who could), you must use effective contraception during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This study tests two immunotherapy medicines (iparomlimab and tuvonralimab) combined with radiation and standard chemotherapy for advanced head and neck cancer that cannot be removed with surgery. The goal is to see if adding these medicines helps shrink tumors and improve outcomes.
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.